{"database":"biostudies-arrayexpress","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown","Transcriptomics","Genomics","Proteomics"],"submitter":["Watip Tangjittipokin"],"study_type":["genotyping by array"],"organism":["Homo sapiens"],"species":["Homo sapiens"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/E-MTAB-15470"],"description":["To investigate the association between polymorphisms in innate immune genes and post-COVID-19 hyperglycemia"],"repository":["biostudies-arrayexpress"],"sample_protocol":["Sample Collection - Peripheral venous blood samples were obtained and processed by centrifugation to separate plasma and buffy coat.","Hybridization - Sample analysis was performed according to the Axiom™ 2.0 Assay Manual Workflow User Guide (Thermo Fisher Scientific Inc.). Briefly, genomic DNA was first amplified, then enzymatically fragmented and precipitated. The DNA was subsequently dried, resuspended, denatured, and hybridized onto Axiom arrays. Post-hybridization steps included ligation, staining, and array scanning. All array processing was conducted using the GeneTitan™ MC Instrument, with instrument control and data analysis carried out using the GeneTitan™ Instrument Control Software and Axiom™ Analysis Suite Software.","Labeling - Sample analysis followed the protocol outlined in the Axiom™ 2.0 Assay Manual Workflow User Guide by Thermo Fisher Scientific Inc.","Scaning - Following ligation, the arrays were stained and imaged using the GeneTitan™ MC Instrument.","Nucleic Acid Extraction - Genomic DNA was extracted from buffy coat using FlexiGene DNA Kit (Qiagen)."],"figure_sub":["MIAME Score","Raw Data","Organization","Assays and Data","MAGE-TAB Files","Array Designs"],"pubmed_authors":["Watip Tangjittipokin"],"additional_accession":[]},"is_claimable":false,"name":"Polymorphisms associated with post-COVID-19 hyperglycemia using the Axiom Human Genotyping SARS-CoV-2 Research Array","description":"To investigate the association between polymorphisms in innate immune genes and post-COVID-19 hyperglycemia","dates":{"release":"2025-08-30T00:00:00Z","modification":"2025-08-30T01:02:12.131Z","creation":"2025-08-08T15:52:03.781Z"},"accession":"E-MTAB-15470","cross_references":{"EFO":["EFO_0002944","EFO_0003814","EFO_0003813","EFO_0002767","EFO_0005518","EFO_0003815"]}}